| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | -0.033 | 0.9 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.0088 | 0.9 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.0086 | 0.9 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.034 | 0.9 |